Assay Automation Makes Reducing-Edge Analysis Extra Accessible to Labs.
Picture Credit score: Beckman Coulter Life Sciences
INDIANAPOLIS – (August 6, 2024) – Beckman Coulter Life Sciences, a worldwide chief in laboratory automation and innovation, in partnership with Illumina, a frontrunner in DNA sequencing and array-based applied sciences, affords a promising new strategy to oncology analysis delivering quicker outcomes with fewer touchpoints. The Illumina TruSight™ Oncology 500 DNA/RNA assay on the Biomek NGeniuS System from Beckman Coulter Life Sciences supplies an modern automated answer enabling complete genomic profiling of tumor samples.
The appliance helps each DNA and RNA inputs, enabling the detection of essential most cancers biomarkers together with single nucleotide variants (SNVs), insertions, deletions, gene amplifications, fusions, and splice occasions. Full library preparation may be achieved in lower than three days, offering quicker outcomes with automated precision from pattern preparation to sequencing.
4 to 24 libraries may be processed in a single batch, accommodating each high-quality and low-quality FFPE samples. The assay can be optimized for decreased plastic use and decrease consumable prices, making cutting-edge analysis extra accessible and sustainable.
“Delivering essential analysis outcomes quicker is paramount in all that we do in subsequent technology sequencing and past,” mentioned Ewan Grant, Senior Director of the Biotech Workflow Options Enterprise Unit at Beckman Coulter Life Sciences. “The continued collaboration with Illumina goals to speed up the journey from pattern to perception, and the launch of this new software demonstrates our dedication to allow our prospects to ship knowledge faster and extra reliably with out the difficulties of handbook workflows.”
The brand new software joins the Illumina DNA Prep, DNA PCR-Free Prep, and RNA Prep with Enrichment purposes, that are all out there in a first-of-its-kind open chemistry, cloud-based Biomek NGeniuS System Purposes Library.
“We’re happy to proceed our collaboration with Beckman Coulter Life Sciences by way of the event of the Illumina DNA PCR Free and Illumina TruSight Oncology 500 DNA methodology to be used on the Biomek NGeniuS liquid dealing with system to allow NGS-based oncology testing,” mentioned Mike Kreitzinger, Senior Director, Scientific Technique & Partnership, Americas at Illumina. “For our mutual prospects, the event of automated strategies on the Biomek NGeniuS System will considerably cut back hands-on time, enhance buyer expertise, and proceed to allow genomics as a essential instrument for medical analysis in oncology.”
Launched in June of 2022, the Biomek NGeniuS System is a purpose-built liquid handler for low-medium throughput subsequent technology sequencing (NGS) library preparation. It supplies an easy-to-use automation answer that reduces user-errors, handbook transfers, and hands-on time for the historically labor-intensive means of NGS library building.
The Illumina TruSight Oncology 500 DNA/RNA pattern preparation methodology and extra purposes centered round most cancers analysis, infectious illness analysis, and focused sequencing is the newest installment in a collection of automation software collaborations between the 2 corporations introduced in February 2022. Extra product info, assets, and software particulars may be discovered by clicking right here.
About Beckman Coulter Life Sciences
With a relentless mission to empower these in search of solutions to life’s essential scientific questions, Beckman Coulter Life Sciences is a most popular laboratory companion offering automation and innovation options for Centrifugation, Circulate Cytometry, Genomics, Particle Evaluation, and Liquid Dealing with workflows. With a legacy relationship again to 1935, our applied sciences cut back handbook laboratory processes and might present higher velocity, accuracy, and superior analytics to speed up solutions with a guiding focus to enhance affected person care and allow pioneering discoveries.
Beckman Coulter Life Sciences is headquartered in Indianapolis, Indiana with 11 operational hubs all over the world and employs roughly 2,800 associates with greater than 400,000 programs put in globally. Get to know us by clicking right here and by following us on LinkedIn.
